Segment Information

9 Months Ended

Sep. 30, 2016

Segment Information

Segment Information

13.Segment Information

We currently operate as one operating segment. Our chief operating decision maker regularly reviews net product sales, cost of product sales and gross profit data as a primary measure of performance for each of our five commercial products.

Net product sales, cost of product sales and gross profit for each of our commercial products were as follows (in millions):

	Three Months Ended September 30,
	Remodulin			Tyvaso		Adcirca		Orenitram		Unituxin			Total
2016
Net product sales	$	152.4		$	101.8	$	96.0	$	40.7	$	17.3		$	408.2
Cost of product sales	3.7			5.8		5.5		5.2		3.4			23.6
Gross profit	$	148.7		$	96.0	$	90.5	$	35.5	$	13.9		$	384.6
2015
Net product sales(1)	$	150.1		$	121.7	$	73.8	$	34.4	$	4.7		$	384.7
Cost of product sales	(2.2		)	3.5		4.5		2.1		(1.0		)	6.9
Gross profit	$	152.3		$	118.2	$	69.3	$	32.3	$	5.7		$	377.8
	Nine Months Ended September 30,
	Remodulin			Tyvaso		Adcirca		Orenitram		Unituxin			Total
2016
Net product sales	$	451.1		$	311.0	$	259.5	$	118.9	$	49.3		$	1,189.8
Cost of product sales	4.3			12.9		15.0		7.9		4.2			44.3
Gross profit	$	446.8		$	298.1	$	244.5	$	111.0	$	45.1		$	1,145.5
2015
Net product sales(1)	$	432.3		$	350.9	$	187.3	$	81.2	$	4.7		$	1,056.4
Cost of product sales	7.1			15.9		11.2		7.6		1.9			43.7
Gross profit	$	425.2		$	335.0	$	176.1	$	73.6	$	2.8		$	1,012.7

(1) Unituxin was approved by the FDA in March 2015 and we commenced sales of Unituxin in the third quarter of 2015.

For the three-month periods ended September 30, 2016 and September 30, 2015, net product sales from our U.S.-based distributors represented 68 percent and 72 percent, respectively, of total revenues. For the nine-month periods ended September 30, 2016 and September 30, 2015, net product sales from our U.S.-based distributors represented 70 percent and 74 percent, respectively, of total revenues. Remaining revenues were derived primarily from net product sales of Adcirca and net product sales of Remodulin, Tyvaso, and Unituxin to our international distributors.